Trial Profile
Rate and Predictors of Relapse in the Treatment of Hepatitis C in Real-Life Clinical Practice in Spanish Hospitals (FAST-4)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms FAST-4
- Sponsors Merck Sharp & Dohme Corp.
- 22 Apr 2012 Actual patient number changed from 278 to 279 as reported by ClinicalTrials.gov.
- 11 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Jan 2011 Planned end date changed from 1 Jan 2011 to 1 Feb 2011 as reported by ClinicalTrials.gov.